NCT02668770 2026-04-07
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
M.D. Anderson Cancer Center
Anaveon AG
SQZ Biotechnologies
Chinese PLA General Hospital
SQZ Biotechnologies